FMP
NASDAQ
4.18 USD
0.21 (5.02%)
Mr. Gerard J. Michel MBA, MS
Healthcare
Medical Devices
https://www.delcath.com
NASDAQ
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System...
0000872912
US24661P8077
24661P807
1633 Broadway
212 489 2100
US
52
May 3, 2018
0000872912
NASDAQ
Medical Devices
Healthcare
24661P807
US24661P8077
US
4.18
0.51
241.14k
92.15M
-
2.25-7.99
10.81
-
-
-
-
-1.22
-
https://www.delcath.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.